• Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT-1 trial 

      Horndalsveen, Henrik; Alver, Tine Norman; Dalsgaard, Astrid Marie; Helbekkmo, Nina; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Ramberg, Christina; Haakensen, Vilde Drageset; Øjlert, Åsa Kristina; Bjaanæs, Maria Moksnes; Helland, Åslaug; Rogg, Lotte Victoria (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-11-04)
      The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non-small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical responses to these drugs and to help monitor the treatment effect. In this phase II trial, we investigated the toxicity, systemic responses and circulating tumour DNA responses in ...
    • Protein kinase C isozymes associated with relapse free survival in non-small cell lung cancer patients 

      Halvorsen, Ann Rita; Haugen, Mads Haugland; Øjlert, Åsa Kristina; Lund-Iversen, Marius; Jørgensen, Lars Hilmar; Solberg, Steinar; Mælandsmo, Gunhild Mari; Brustugun, Odd Terje; Helland, Åslaug (Journal article; Tidsskriftartikkel, 2020-11-25)
      <i>Introduction</i>: Protein expression is deregulated in cancer, and the proteomic changes observed in lung cancer may be a consequence of mutations in essential genes. The purpose of this study was to identify protein expression associated with prognosis in lung cancers stratified by smoking status, molecular subtypes, and EGFR-, TP53-, and KRAS-mutations.<p> <p><i>Methods</i>: We performed ...